-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V5/ZXsFDwdTtiRYkaujuPKjGKljGeh1MOGiwSIvnn6GYlXCYRjLaaEiPISzssA10 ZQPes9qagiIX0ldyC7jdUQ== 0001104659-11-009106.txt : 20110223 0001104659-11-009106.hdr.sgml : 20110223 20110223070702 ACCESSION NUMBER: 0001104659-11-009106 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20110223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110223 DATE AS OF CHANGE: 20110223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 11630473 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 8-K 1 a11-6511_18k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): February 23, 2011

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

 

000-30833
(Commission
File Number)

 

04-3110160
(IRS Employer
Identification No.)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act

 

o            Soliciting material pursuant to Rule 14a-12 of the Exchange Act

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

 



 

Section 2 — Financial Information

 

Item 2.02.  Results of Operations and Financial Condition

 

On February 23, 2011, Bruker Corporation issued a press release announcing combined financial results as of and for the three and twelve months ended December 31, 2010.  A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Section 9 — Financial Statements and Exhibits

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)          Exhibits

 

Number

 

 

 

 

 

99.1

 

Press release dated February 23, 2011.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION

 

(Registrant)

 

 

Date: February 23, 2011

By:

/s/ BRIAN P. MONAHAN

 

 

Brian P. Monahan

 

 

Chief Financial Officer

 

3



 

Exhibit Index

 

Exhibit
Number

 

Exhibit Name

 

Location

 

 

 

 

 

99.1

 

Press release dated February 23, 2011.

 

Furnished herewith*

 


*        Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

4


EX-99.1 2 a11-6511_1ex99d1.htm EX-99.1

Exhibit 99.1

 

Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2010

 

BILLERICA, Mass., February 23, 2011 (BUSINESS WIRE) —  Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2010.

 

Fourth Quarter and Full Year 2010 Highlights

 

·                  Fourth quarter Bruker currency-adjusted revenue grew by 17% year-over year to $416.1 million

·                  Fourth quarter adjusted operating margin for the Bruker Scientific Instruments (BSI) segment was 16.8%

·                  Fourth quarter adjusted EPS for BSI was $0.28 (above our October 2010 guidance of greater than $0.21)

·                  Closed acquisition of new Bruker Nano Surfaces (BNS) division from Veeco in the fourth quarter: BNS is forecasted to contribute revenue greater than $130 million and adjusted operating margin greater than 15% in 2011.

 

·                  Full year Bruker currency-adjusted revenue grew by 18% to $1.305 billion (exceeding our 2010 goal of currency-adjusted revenue growth greater than 5%)

·                  Full year BSI adjusted operating margin was 14.8%, an increase of 190 basis points compared to 2009 BSI adjusted operating margin of 12.9% (exceeding our 2010 goal of BSI adjusted operating margin expansion by greater than 125 basis points)

·                  Full year adjusted EPS for BSI was $0.76, an increase of 49% over 2009 BSI adjusted EPS of $0.51 (exceeding our 2010 goal to grow BSI EPS by greater than 15%)

 

·                  Full year currency-adjusted Bruker Energy & Supercon Technologies (BEST) segment revenue grew 59% (exceeding our 2010 goal of greater than 25% BEST revenue growth)

·                  Full year BEST adjusted operating loss was $2.3 million (better than our goal of 2010 BEST operating loss of $7-8 million)

·                  For the full year 2010, BEST achieved approximately EBITDA break-even

 

·                  Full year Bruker operating cash flow was $156.1 million, and free cash flow was $124.2 million

·                  Full year BSI Return on Invested Capital (RoIC) was 32.6% (defined below in section ‘Use of Non-GAAP Measures’)

 

Financial Results

 

In the fourth quarter of 2010, Bruker’s GAAP revenue increased by 13% to $416.1 million, compared to revenue of $366.4 million in the fourth quarter of 2009.  Excluding

 



 

the effects of foreign currency translation, Bruker’s fourth quarter revenue increased by 17% year-over-year.  In the fourth quarter of 2010, currency-adjusted revenue increased by 15% year-over-year for the BSI segment, and by 33% for the BEST segment.

 

Adjusted Bruker net income for the fourth quarter of 2010 was $45.3 million, or $0.27 per diluted share, compared to adjusted net income of $40.2 million, or $0.24 per diluted share, in the fourth quarter of 2009.  In the fourth quarter of 2010, BSI contributed adjusted EPS of $0.28, and BEST had a net loss per share of ($0.01).

 

For the year 2010, Bruker’s GAAP revenue increased by 17% to $1.305 billion, compared to revenue of $1.115 billion for the year 2009.  Excluding the effects of foreign currency translation, Bruker’s full year 2010 revenue increased by 18% year-over-year.  For the year 2010, currency-adjusted revenue increased by 16% year-over-year for BSI, and by 59% for BEST.

 

Adjusted operating income for BSI in 2010 was $181.8 million, or 14.8% of revenue, compared to $136.6 million, or 12.9% of revenue in 2009.  For the year 2010, BEST adjusted operating loss was $2.3 million, compared to an adjusted operating loss of $5.7 million in 2009.

 

Bruker’s adjusted net income for the year 2010 was $118.7 million, or $0.72 per diluted share, compared to adjusted net income of $78.5 million, or $0.47 per diluted share, for the year 2009, an increase of 53%.  For the full year 2010, BSI contributed adjusted earnings of $0.76 per diluted share, compared to $0.51 in 2009.  For each of the years 2010 and 2009, BEST contributed an adjusted net loss of ($0.04) per diluted share.

 

Bruker’s cash flow from operations for the full year 2010 was $156.1 million, compared to $149.8 million in 2009.  As of December 31, 2010, Bruker had cash, cash equivalents and restricted cash of $233.3 million and net debt of $67.7 million.

 

Comment and Outlook

 

“Bruker celebrated its 50th anniversary in 2010, as we continued to strengthen our market position by remaining true to our core competencies of delivering innovative, high performance and customer-focused life-science and analytical instruments,” said Frank Laukien, President and CEO of Bruker. “Our emphasis on product innovation, organic growth, disciplined acquisitions and operational excellence enabled us to deliver record revenues, operating income and earnings per share, significantly exceeding our full-year 2010 financial goals.”

 

He continued: “We see positive signs globally regarding spending by our industrial, biopharma, clinical and applied markets customers, and we remain confident that academic and government research budgets in most key countries will be stable or will grow in 2011.  With encouraging signs in our end markets, strong order momentum, record backlog and a continued focus on margin expansion and operational excellence,

 



 

we expect to generate further improvements in our financial performance in 2011 and beyond.”

 

Financial Goals 2011

 

Bruker’s financial goals for the full year 2011 are:

 

·                  Currency-adjusted Bruker revenue growth of greater than 18%, to reach Bruker revenue of $1.55 billion to $1.57 billion,

·              BSI adjusted operating margin improvement of greater than 75 basis points,

·              BSI adjusted EPS of approximately $0.90 to $0.93,

·              BSI $0.46 of working capital per revenue dollar in 2011, a further improvement compared to $0.49 in 2010, and

·              maintaining a BSI RoIC of greater than 30% in 2011.

 

Medium-Term Financial Goals 2014

 

Our previous medium-term financial goals, which we had adopted in early 2009, targeted a 15% BSI adjusted operating margin by 2012.  As we now anticipate that BSI will exceed its 15% target one year earlier in 2011, we are establishing new medium-term financial targets for the full year 2014:

 

·                  Currency-adjusted revenue CAGR of greater than 10% in the years 2012 to 2014, to reach a Bruker revenue target of greater than $2 billion in 2014, and

·                  Average annual BSI adjusted operating margin expansion by 75-100 bps in the years 2012-2014, with a BSI adjusted operating margin target of greater than 18% in 2014.

 

Use of Non-GAAP Financial Measures

 

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude acquisition-related and restructuring and other charges. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts.

 

For example:

 

We exclude certain acquisition-related charges or credits and associated tax effects, including charges for the sale of inventories revalued at the date of acquisition, significant transaction costs such as legal fees and credits associated with bargain

 



 

purchases. We exclude these costs because we do not believe they are indicative of our normal operating costs.

 

We exclude charges and tax effects associated with restructuring and business divestiture activities, such as reducing overhead and consolidating facilities. We believe that the costs related to these restructuring and business divestiture activities are not indicative of our normal operating costs.

 

We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of 3 to 10 years. Exclusion of these non-cash amortization expenses allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses.

 

We exclude certain gains/losses associated with significant tax audits or events which cannot be expected to occur with regularity or predictability and that we believe are not indicative of typical gains and losses.

 

We discuss the metric Return on Invested Capital (RoIC), which we deem important because RoIC is a measure which provides management with a means to analyze and improve our business by measuring profitability in relation to capital investments.  We calculate RoIC using adjusted operating income after tax, divided by average invested capital, which is the average of equity plus net debt, at the beginning and end of year.

 

Bruker’s management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company’s core operating performance and comparing such performance to that of prior periods and to the performance of our competitors.  Such measures are also used by management in their financial and operating decision-making and for compensation purposes.

 

The non-GAAP financial measures of Bruker’s results of operations included in this press release are not meant to be considered superior to or a substitute for Bruker’s results of operations prepared in accordance with GAAP.  Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables.

 

EARNINGS CONFERENCE CALL

 

Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Time on Wednesday, February 23, 2011.  To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or +1-617-614-4070 outside the US and Canada.  Investors should refer to the Bruker Earnings Call.  A telephone replay of the conference call will be available one hour after the conference

 



 

call by dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 24610364.  For more information, please visit http://ir.bruker.com

 

CAUTIONARY STATEMENT OF BRUKER CORPORATION

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental re gulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

 

CAUTIONARY STATEMENT OF BEST

 

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “continue” or other similar words.

 

These forward-looking statements are predictions, not guarantees. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those projected, include, but are not limited to, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intel lectual property rights, litigation, and

 



 

exposure to foreign currency fluctuations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.

 

The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

 



 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

December 31,

 

December 31,

 

(in millions, except per share amounts)

 

2010

 

2009

 

2010

 

2009

 

Revenues

 

$

 416.1

 

$

 366.4

 

$

 1,304.9

 

$

 1,114.5

 

Cost of revenues

 

219.0

 

180.9

 

698.9

 

595.9

 

Gross profit

 

197.1

 

185.5

 

606.0

 

518.6

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

95.4

 

73.2

 

297.3

 

253.3

 

Research and development

 

44.9

 

34.6

 

141.4

 

126.4

 

Amortization of acquisition-related intangible assets

 

3.7

 

0.5

 

5.8

 

1.8

 

Other charges, net

 

1.5

 

1.0

 

5.8

 

0.4

 

Total operating expenses

 

145.5

 

109.3

 

450.3

 

381.9

 

Operating income

 

51.6

 

76.2

 

155.7

 

136.7

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense), net

 

 

(3.0

)

(5.6

)

(7.6

)

 

 

 

 

 

 

 

 

 

 

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

51.6

 

73.2

 

150.1

 

129.1

 

Income tax provision

 

21.6

 

29.6

 

53.3

 

48.1

 

 

 

 

 

 

 

 

 

 

 

Consolidated net income

 

30.0

 

43.6

 

96.8

 

81.0

 

Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries

 

0.7

 

0.1

 

1.4

 

(0.2

)

Net income attributable to Bruker Corporation

 

$

 29.3

 

$

 43.5

 

$

 95.4

 

$

 81.2

 

 

 

 

 

 

 

 

 

 

 

Net income per common share attributable to

 

 

 

 

 

 

 

 

 

Bruker Corporation shareholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

 0.18

 

$

 0.27

 

$

 0.58

 

$

 0.50

 

Diluted

 

$

 0.18

 

$

 0.26

 

$

 0.58

 

$

 0.49

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

164.7

 

163.8

 

164.4

 

163.5

 

Diluted

 

166.1

 

165.2

 

165.7

 

164.9

 

 



 

Reconciliation of adjusted operating income, net income and earnings per share for the three and twelve months ended December 31, 2010 and 2009 (unaudited) (a) (b)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

 

December 31,

 

December 31,

 

(in millions, except per share amounts)

 

2010

 

2009

 

2010

 

2009

 

Reconciliation of Adjusted Operating Income

 

 

 

 

 

 

 

 

 

GAAP operating income (a)

 

$

51.6

 

$

76.2

 

$

155.7

 

$

136.7

 

Cost of revenues charges/(credits) (c)

 

5.5

 

(6.7

)

7.2

 

(6.7

)

Amortization of acquisition-related intangible assets (d)

 

3.7

 

0.5

 

5.8

 

1.8

 

Other charges (e)

 

4.3

 

1.0

 

8.6

 

0.4

 

Adjusted operating income

 

$

65.1

 

$

71.0

 

$

177.3

 

$

132.2

 

Adjusted operating margins

 

15.6

%

19.4

%

13.6

%

11.9

%

 

 

 

 

 

 

 

 

 

 

Reconciliation of Adjusted Net Income

 

 

 

 

 

 

 

 

 

GAAP net income (a)

 

$

29.3

 

$

43.5

 

$

95.4

 

$

81.2

 

Cost of revenues charges/(credits) (c)

 

5.3

 

(4.7

)

6.9

 

(4.7

)

Amortization of acquisition-related intangible assets (d)

 

3.4

 

0.4

 

5.3

 

1.6

 

Other charges (e)

 

7.3

 

1.0

 

11.1

 

0.4

 

Adjusted net income

 

$

45.3

 

$

40.2

 

$

118.7

 

$

78.5

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of Adjusted Earnings Per Share

 

 

 

 

 

 

 

 

 

GAAP earnings per share (a)

 

$

0.18

 

$

0.26

 

$

0.58

 

$

0.49

 

Cost of revenues charges/(credits) (c)

 

0.03

 

(0.03

)

0.04

 

(0.03

)

Amortization of acquisition-related intangible assets (d)

 

0.02

 

 

0.03

 

0.01

 

Other charges (e)

 

0.04

 

0.01

 

0.07

 

 

Adjusted earnings per share

 

$

0.27

 

$

0.24

 

$

0.72

 

$

0.47

 

 


(a)

 

“GAAP” (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP)

(b)

 

Adjusted results are non-GAAP measures and for income measures exclude certain charges to cost of revenues (see note c for details); amortization of acquisition-related intangible assets (see note d for details); restructuring and other charges (see note e for details); and the tax consequences of the preceding items

(c)

 

Reported results in 2010 include charges for the sale of inventories revalued at the date of acquisition. Reported results in 2009 contain a favorable impact for the recognition of a system in which a majority of costs were expensed in historical periods through research and development expense.

(d)

 

Reported results in 2010 and 2009 include charges for the amortization of acquisition-related intangible assets

(e)

 

Reported results within other charges in 2010 include $7.4 million of various costs incurred in connection with acquisitions, $1.0 million of charges associated with the divestiture of a manufacturing facility and $0.2 million of restructuring costs. Of these costs, approximately $4.3 million were incurred in the fourth quarter of 2010. Reported results within other charges in 2009 included a net loss of $0.2 million incurred in connection with the acquisition of ACCEL Instruments and $0.2 million of restructuring costs. Approximately $0.8 million of the acquisition charges and $0.2 million of the restructuring charges were incurred in the fourth quarter of 2009.

 

The charges described in notes c, d and e have been tax effected using enacted tax rates in the jurisdiction in which the charge was recorded. In addition, Reported results in the fourth quarter and full year 2010 included charges of $3.1 million associated with income taxes for historical periods under audit.

 



 

Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the three and twelve months ended December 31, 2010 and 2009 (unaudited) (a) (b)

 

 

 

 

 

Bruker

 

 

 

 

 

 

 

Bruker

 

Energy &

 

Corporate,

 

Consolidated

 

Segment Data 

 

Scientific

 

Supercon

 

Adjustments

 

Bruker

 

(in millions, except per share amounts)

 

Instruments

 

Technologies

 

& Eliminations

 

Corporation

 

Three Months Ended December 31, 2010:

 

 

 

 

 

 

 

 

 

Revenue

 

$

389.4

 

$

29.3

 

$

(2.6

)

$

416.1

 

 

 

 

 

 

 

 

 

 

 

Gross profit - GAAP

 

$

191.7

 

$

6.2

 

$

(0.8

)

$

197.1

 

Cost of revenues charges (c)

 

5.5

 

 

 

5.5

 

Gross profit - adjusted

 

$

197.2

 

$

6.2

 

$

(0.8

)

$

202.6

 

Gross profit margin - adjusted

 

50.6

%

21.2

%

 

 

48.7

%

 

 

 

 

 

 

 

 

 

 

Operating income (loss) - GAAP

 

$

52.0

 

$

0.4

 

$

(0.8

)

$

51.6

 

Cost of revenues charges (c)

 

5.5

 

 

 

5.5

 

Amortization of acquisition-related intangible assets (d)

 

3.7

 

 

 

3.7

 

Other charges (e)

 

4.3

 

 

 

4.3

 

Operating income (loss) - adjusted

 

$

65.5

 

$

0.4

 

$

(0.8

)

$

65.1

 

Operating margin - adjusted

 

16.8

%

1.4

%

 

 

15.6

%

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Bruker Corporation - GAAP

 

$

31.7

 

$

(1.9

)

$

(0.5

)

$

29.3

 

Cost of revenues charges (c)

 

5.3

 

 

 

5.3

 

Amortization of acquisition-related intangible assets (d)

 

3.4

 

 

 

3.4

 

Other charges (e)

 

7.3

 

 

 

7.3

 

Net income (loss) attributable to Bruker Corporation - adjusted

 

$

47.7

 

$

(1.9

)

$

(0.5

)

$

45.3

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share attributable to Bruker Corporation - GAAP

 

$

0.19

 

$

(0.01

)

$

(0.00

)

$

0.18

 

Cost of revenues charges (c)

 

0.03

 

 

 

0.03

 

Amortization of acquisition-related intangible assets (d)

 

0.02

 

 

 

0.02

 

Other charges (e)

 

0.04

 

 

 

0.04

 

Diluted net income (loss) per common share attributable to Bruker Corporation - adjusted

 

$

0.28

 

$

(0.01

)

$

(0.00

)

$

0.27

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

166.1

 

164.7

 

164.7

 

166.1

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended December 31, 2009:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

346.2

 

$

23.8

 

$

(3.6

)

$

366.4

 

 

 

 

 

 

 

 

 

 

 

Gross profit - GAAP

 

$

183.0

 

$

2.8

 

$

(0.3

)

$

185.5

 

Cost of revenues credits (c)

 

(6.7

)

 

 

(6.7

)

Gross profit - adjusted

 

$

176.3

 

$

2.8

 

$

(0.3

)

$

178.8

 

Gross profit margin - adjusted

 

50.9

%

11.8

%

 

 

48.8

%

 

 

 

 

 

 

 

 

 

 

Operating income (loss) - GAAP

 

$

78.3

 

$

(2.0

)

$

(0.1

)

$

76.2

 

Cost of revenues credits (c)

 

(6.7

)

 

 

(6.7

)

Amortization of acquisition-related intangible assets (d)

 

0.4

 

0.1

 

 

0.5

 

Other charges, net (e)

 

0.2

 

0.8

 

 

1.0

 

Operating income (loss) - adjusted

 

$

72.2

 

$

(1.1

)

$

(0.1

)

$

71.0

 

Operating margin - adjusted

 

20.9

%

(4.6

)%

 

 

19.4

%

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Bruker Corporation - GAAP

 

$

45.5

 

$

(1.9

)

$

(0.1

)

$

43.5

 

Cost of revenues credits (c)

 

(4.7

)

 

 

(4.7

)

Amortization of acquisition-related intangible assets (d)

 

0.3

 

0.1

 

 

0.4

 

Other charges, net (e)

 

0.2

 

0.8

 

 

1.0

 

Net income (loss) attributable to Bruker Corporation - adjusted

 

$

41.3

 

$

(1.0

)

$

(0.1

)

$

40.2

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share attributable to Bruker Corporation - GAAP

 

$

0.27

 

$

(0.01

)

$

(0.00

)

$

0.26

 

Cost of revenues credits (c)

 

(0.03

)

 

 

(0.03

)

Amortization of acquisition-related intangible assets (d)

 

 

 

 

 

Other charges, net (e)

 

 

0.01

 

 

0.01

 

Diluted net income (loss) per common share attributable to Bruker Corporation - adjusted

 

$

0.24

 

$

(0.00

)

$

(0.00

)

$

0.24

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

165.2

 

163.8

 

163.8

 

165.2

 

 



 

 

 

 

 

Bruker

 

 

 

 

 

 

 

Bruker

 

Energy &

 

Corporate,

 

Consolidated

 

Segment Data 

 

Scientific

 

Supercon

 

Adjustments

 

Bruker

 

(in millions, except per share amounts)

 

Instruments

 

Technologies

 

& Eliminations

 

Corporation

 

Twelve Months Ended December 31, 2010:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

1,225.1

 

$

90.5

 

$

(10.7

)

$

1,304.9

 

 

 

 

 

 

 

 

 

 

 

Gross profit - GAAP

 

$

591.7

 

$

16.6

 

$

(2.3

)

$

606.0

 

Cost of revenues charges (c)

 

7.2

 

 

 

7.2

 

Gross profit - adjusted

 

$

598.9

 

$

16.6

 

$

(2.3

)

$

613.2

 

Gross profit margin - adjusted

 

48.9

%

18.3

%

 

 

47.0

%

 

 

 

 

 

 

 

 

 

 

Operating income (loss) - GAAP

 

$

160.5

 

$

(2.6

)

$

(2.2

)

$

155.7

 

Cost of revenues charges (c)

 

7.2

 

 

 

7.2

 

Amortization of acquisition-related intangible assets (d)

 

5.5

 

0.3

 

 

5.8

 

Other charges (e)

 

8.6

 

 

 

8.6

 

Operating income (loss) - adjusted

 

$

181.8

 

$

(2.3

)

$

(2.2

)

$

177.3

 

Operating margin - adjusted

 

14.8

%

(2.5

)%

 

 

13.6

%

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Bruker Corporation - GAAP

 

$

103.4

 

$

(6.4

)

$

(1.6

)

$

95.4

 

Cost of revenues charges (c)

 

6.9

 

 

 

6.9

 

Amortization of acquisition-related intangible assets (d)

 

5.0

 

0.3

 

 

5.3

 

Other charges (e)

 

11.1

 

 

 

11.1

 

Net income (loss) attributable to Bruker Corporation - adjusted

 

$

126.4

 

$

(6.1

)

$

(1.6

)

$

118.7

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share attributable to Bruker Corporation - GAAP

 

$

0.62

 

$

(0.04

)

$

(0.00

)

$

0.58

 

Cost of revenues charges (c)

 

0.04

 

 

 

0.04

 

Amortization of acquisition-related intangible assets (d)

 

0.03

 

 

 

0.03

 

Other charges (e)

 

0.07

 

 

 

0.07

 

Diluted net income (loss) per common share attributable to Bruker Corporation - adjusted

 

$

0.76

 

$

(0.04

)

$

(0.00

)

$

0.72

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

165.7

 

164.4

 

164.4

 

165.7

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended December 31, 2009:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

1,062.7

 

$

59.8

 

$

(8.0

)

$

1,114.5

 

 

 

 

 

 

 

 

 

 

 

Gross profit - GAAP

 

$

508.9

 

$

8.6

 

$

1.1

 

$

518.6

 

Cost of revenues credits (c)

 

(6.7

)

 

 

(6.7

)

Gross profit - adjusted

 

$

502.2

 

$

8.6

 

$

1.1

 

$

511.9

 

Gross profit margin - adjusted

 

47.3

%

14.4

%

 

 

45.9

%

 

 

 

 

 

 

 

 

 

 

Operating income (loss) - GAAP

 

$

141.7

 

$

(6.3

)

$

1.3

 

$

136.7

 

Cost of revenues credits (c)

 

(6.7

)

 

 

(6.7

)

Amortization of acquisition-related intangible assets (d)

 

1.4

 

0.4

 

 

1.8

 

Other charges, net (e)

 

0.2

 

0.2

 

 

0.4

 

Operating income (loss) - adjusted

 

$

136.6

 

$

(5.7

)

$

1.3

 

$

132.2

 

Operating margin - adjusted

 

12.9

%

(9.5

)%

 

 

11.9

%

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Bruker Corporation - GAAP

 

$

87.2

 

$

(6.9

)

$

0.9

 

$

81.2

 

Cost of revenues credits (c)

 

(4.7

)

 

 

(4.7

)

Amortization of acquisition-related intangible assets (d)

 

1.2

 

0.4

 

 

1.6

 

Other charges, net (e)

 

0.2

 

0.2

 

 

0.4

 

Net income (loss) attributable to Bruker Corporation - adjusted

 

$

83.9

 

$

(6.3

)

$

0.9

 

$

78.5

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share attributable to Bruker Corporation - GAAP

 

$

0.53

 

$

(0.04

)

$

 

$

0.49

 

Cost of revenues credits (c)

 

(0.03

)

 

 

(0.03

)

Amortization of acquisition-related intangible assets (d)

 

0.01

 

 

 

0.01

 

Other charges, net (e)

 

 

 

 

 

Diluted net income (loss) per common share attributable to Bruker Corporation - adjusted

 

$

0.51

 

$

(0.04

)

$

 

$

0.47

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

164.9

 

163.5

 

164.9

 

164.9

 

 



 

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

 

 

 

December 31,

 

December 31,

 

(in millions)

 

2010

 

2009

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash, cash equivalents and restricted cash

 

$

233.3

 

$

209.1

 

Accounts receivable, net

 

232.9

 

184.1

 

Inventories

 

511.0

 

422.8

 

Other current assets

 

73.9

 

57.8

 

Total current assets

 

1,051.1

 

873.8

 

 

 

 

 

 

 

Property, plant and equipment, net

 

233.7

 

223.4

 

Intangible and other long-term assets

 

265.0

 

75.1

 

 

 

 

 

 

 

Total assets

 

$

1,549.8

 

$

1,172.3

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Short-term borrowings, including current portion of long-term debt

 

$

214.4

 

$

22.0

 

Accounts payable

 

64.0

 

49.8

 

Customer advances

 

242.2

 

219.2

 

Other current liabilities

 

310.9

 

249.5

 

Total current liabilities

 

831.5

 

540.5

 

 

 

 

 

 

 

Long-term debt

 

86.6

 

115.7

 

Other long-term liabilities

 

104.3

 

97.3

 

 

 

 

 

 

 

Total shareholders’ equity

 

527.4

 

418.8

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

1,549.8

 

$

1,172.3

 

 

FOR FURTHER INFORMATION:

Stacey Desrochers, Director of Investor Relations

 

Tel: +1 (978) 663-3660, ext. 1115

 

Email: stacey.desrochers@bruker.com

 


 

-----END PRIVACY-ENHANCED MESSAGE-----